Berkeley Capital Partners LLC Buys New Position in Becton, Dickinson and Company $BDX

Berkeley Capital Partners LLC purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 8,507 shares of the medical instruments supplier’s stock, valued at approximately $1,592,000.

Other large investors have also modified their holdings of the company. Activest Wealth Management grew its position in shares of Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 97 shares during the last quarter. SOA Wealth Advisors LLC. raised its position in Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 95 shares during the last quarter. Bell Investment Advisors Inc grew its position in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the last quarter. Cornerstone Planning Group LLC grew its position in Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 139 shares during the last quarter. Finally, Grey Fox Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company in the third quarter valued at about $32,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.2%

NYSE:BDX opened at $182.29 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $185.02. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The stock has a fifty day moving average price of $197.64 and a two-hundred day moving average price of $192.19. The stock has a market capitalization of $51.91 billion, a price-to-earnings ratio of 29.74, a PEG ratio of 13.24 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period in the prior year, the company posted $3.43 EPS. The business’s revenue for the quarter was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has authorized a stock buyback plan on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This trade represents a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,416 shares of company stock valued at $675,557. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on BDX. Zacks Research lowered Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Jefferies Financial Group lowered their target price on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. TD Cowen upped their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Royal Bank Of Canada set a $172.00 price objective on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.